Kidney Cancer

P2, N=15, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Nov 2026

This study investigated the renoprotective action of linagliptin compared to doxorubicin against thioacetamide (TAA) and diethyl nitrosamine (DEN)-induced renocarcinogenesis in a rat model. These findings demonstrate that linagliptin, especially at 6 mg/kg/day, exhibits significant renoprotective activities through multifarious mechanisms involving antioxidant action and regulation of key molecular pathways. The present study presents evidence for the potential therapeutic application of linagliptin in renal manifestations of renocarcinogenesis.

We herein describe a 67-year old male with bilateral synchronous masses treated with open bilateral adrenal sparing radical nephrectomy. His final pathology was interestingly found to have novel, differing aggressive cancers: a TFE3-rearranged RCC and a grade 4 WHO clear cell RCC.

This study presents a novel and effective strategy to induce the abscopal effect through a synergistic combination of targeted drug delivery, radiotherapy, and immunotherapy. The approach offers strong translational potential for improving radioimmunotherapy outcomes in renal and potentially other immunogenic cancers.

P=N/A, N=40, Recruiting, NYU Langone Health | Trial completion date: Jun 2025 --> Sep 2026 | Trial primary completion date: Feb 2025 --> Jun 2026

EVT is a rare renal tumor entity with characteristic imaging features, though its imaging presentation may vary depending on the underlying pathology. Accurate identification of EVT will contribute to improving the classification and diagnosis of renal tumors.

In conclusion, molecular imaging is increasingly recognized as a valuable tool in the diagnosis and management of RCC. Larger, multicenter studies are essential to define its role in routine clinical practice and to fully explore its potential in future theranostic applications.

Gyp LI upregulates DUSP1 to suppress the metabolism of choline, linoleic acid, and alpha-linolenic acid, ultimately suppressing the incidence and progression of ccRCC.

P2, N=30, Not yet recruiting, Fudan University

3D-SMI provides three-dimensional visualization of Vascular Architecture. Quantitative analysis of the most vascularized plane using Area and VI differentiation between benign and malignant renal tumors, with VI demonstrating the best diagnostic efficacy. This technique offers a non-invasive diagnostic approach for renal tumors.

However, it can be difficult to identify malignant tumors in a polycystic kidney using imaging alone, and pathological confirmation by biopsy is often required. The present report highlights the usefulness of performing needle biopsy for suspected masses using the same method that is used by nephrologists for kidney biopsy in cases in which determining the lesion nature from imaging alone is difficult and in hydratase-deficient renal cell carcinoma arising in acquired cystic kidney disease as a dialysis-associated renal carcinoma.

The immunohistochemistry profile was positive for pancytokeratin, CD10, and vimentin but negative for PAX8, indicating a distinct appearance in RCC patients. This case emphasizes the necessity of recognizing cutaneous metastases as an uncommon presentation of advanced RCC, as well as PAX8's potential role as a diagnostic marker.